Patti Walters
Acute Care · Brazil, INNPI 1851569131
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 25.1% of the total. 2025 is the largest year on record at $751, more than ten times the $41 reported in 2021.
Across 82 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$375
- GSK$180
- AstraZeneca$167
- Lilly USA, LLC$167
- Boston Scientific$104
- Corcept Therapeutics$92
- plus $408 from 15 others
What the payments were for
- Food & beverage$1,47098%
- Education$232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $375 |
| GSK | 8 | $180 |
| AstraZeneca | 8 | $167 |
| Lilly USA, LLC | 11 | $167 |
| Boston Scientific | 4 | $104 |
| Corcept Therapeutics | 4 | $92 |
| Amgen | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Exact Sciences | 2 | $38 |
| Boehringer Ingelheim | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Vertex | 1 | $29 |
| Novartis | 1 | $26 |
| Shield Therapeutics Inc | 1 | $24 |
| Abbott | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$1,493 in reported general payments places this provider in the 75th percentile of 240 acute care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $90,785 |
| OzempicSemaglutide | 57 | $83,009 |
| EliquisApixaban | 49 | $41,307 |
| TrulicityDulaglutide | 30 | $28,816 |
| JardianceEmpagliflozin | 18 | $25,081 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $14,469 |
| FarxigaDapagliflozin Propanediol | 14 | $9,117 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $8,241 |
| VascepaIcosapent Ethyl | 13 | $5,385 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $5,102 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 27 | $4,616 |
| DexilantDexlansoprazole | 13 | $4,249 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,664 |
| Nebivolol Hcl | 32 | $1,937 |
| Omeprazole | 125 | $1,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $167 | $120,857106 claims |
| Novo NordiskOzempic | $375 | $83,00957 claims |
| Boehringer IngelheimJardiance | $37 | $25,08118 claims |
| GSKAnoro Ellipta, Breo Ellipta | $180 | $22,71039 claims |
| AstraZenecaFarxiga, Symbicort | $167 | $11,78125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 240 acute care providers in Indiana.
Other acute care in Brazil
- Melissa LorenzJeffersonville$19K
- Amara Wright-TerryMunster$17K
- Wen CaiNewburgh$12K
- Erin BarthSouth Bend$10K
- Sarah LongNewburgh$8K
- Aaron HoldermanNewburgh$8K
- Lauren ArmingtonIndianapolis$7K
- Ashley HillIndianapolis$7K
- Sara RichesonNewburgh$6K
- Sarah KachmanTerre Haute$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.